<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118040</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00453</org_study_id>
    <secondary_id>NCI-2013-00453</secondary_id>
    <secondary_id>CDR0000433520</secondary_id>
    <secondary_id>WCCC-UWI03-1-01</secondary_id>
    <secondary_id>WCCC-H-2005-0026</secondary_id>
    <secondary_id>WCCC-CO-04307</secondary_id>
    <secondary_id>UWI03-1-01</secondary_id>
    <secondary_id>UWI03-1-01</secondary_id>
    <secondary_id>N01CN35153</secondary_id>
    <nct_id>NCT00118040</nct_id>
  </id_info>
  <brief_title>Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer</brief_title>
  <official_title>Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may
      help doctors learn more about changes that may occur in DNA and identify biomarkers related
      to cancer. It may also help doctors learn how genistein or placebo works in patients with
      bladder cancer. This randomized phase II trial is studying genistein or placebo to compare
      how they work in patients who are undergoing surgery for bladder cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To measure the effect of G-2535 on EGF-R phosphorylation. Two EGF-R phosphorylation sites
      with functional significance are phosphotyrosine 992, which is a direct binding site for the
      PLC-gamma SH2 domain, and phosphotyrosine 1068, a binding site for the Grb2/SH2 domain. The
      expression of EGF-R and phosphorylated EGF-R will be determined in tumors as well as adjacent
      and remote normal appearing urothelium.

      SECONDARY OBJECTIVES:

      I. Measuring tissue intermediate endpoint biomarkers such as EGF-R mutations (EGFR vIII, exon
      19-21), Ki67, activated Caspase 3, Akt, P-Akt, MAP kinase, P-MAP kinase, COX-2, survivin, and
      BLCA-4 and we will also determine survivin and BLCA-4 levels in urine specimens as surrogate
      tumor markers. Biomarkers associated with the EGF-R pathway, including Akt and P-Akt will be
      studied by immunohistochemistry. Additionally, Ki67, activated Caspase 3 (as a marker of
      apoptosis), and COX-2 will serve as biological endpoint biomarkers to measure the effects of
      G-2535 on proliferation, apoptosis, and other processes and molecules relevant to bladder
      cancer. These studies will be performed on tumors as well as adjacent and remote normal
      urothelium. II. Safety will also be studied.

      OUTLINE: This is a randomized, placebo-controlled, multicenter study. Patients are stratified
      according to invasiveness of disease (non-invasive [stage Ta, Tis, or T1] vs invasive [stage
      T2, T3, or T4]). Patients are randomized to 1 of 3 treatment arms.

      Arm I: Patients receive oral genistein twice daily for approximately 14-30 days.

      Arm II: Patients receive oral genistein as in arm I but at a higher dose. Arm III: Patients
      receive oral placebo twice daily for approximately 14-30 days.

      One day after completion of genistein or placebo, all patients undergo cystoscopic excision,
      transurethral resection of the bladder tumor, or cystectomy.

      Patients undergo blood, urine, and tissue sample collection for pharmacogenomic,
      pharmacokinetic, and biomarker laboratory studies. Blood and urine samples are collected at
      baseline, after 1 week of treatment, and at the time of surgery for pharmacokinetic and urine
      biomarker (survivin and BLCA-4) studies. Pharmacogenomic studies (epidermal growth factor
      receptor [EGFR] polymorphisms and CYP3A 4/5 genotypes) are performed at baseline using blood
      samples. Tissue biomarker (EGFR polymorphism, EGFR mutations [EGFR vIII, exon 19-21], EGFR,
      phosphorylated EGFR, Ki67, activated caspase 3, Akt, P-Akt, MAP kinase, P-MAP kinase, COX-2,
      survivin, and BLCA4) studies using tumor tissue and adjacent and remote normal urothelium are
      performed at baseline and at the completion of treatment.

      PROJECTED ACCRUAL: A total of 60 patients (20 per treatment arm) will be accrued for this
      study within 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epidermal Growth Factor Receptor (EGFR) Phosphorylation in Tumor Tissue, as Measured by Immunohistochemistry After the Completion of Treatment</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pEGFR in Benign Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, pEGFR, in the benign tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BLCA-4 in Urine by Visit</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Detecting the mean amount of the biomarker BLCA-4 in the urine of patients prior to starting study agent, at Day 8 and pre-surgery time (when they have been on study agent between 14-21 days). This is measured by urine analysis at each of the time points to serve as a surrogate tumor marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survivin in Urine by Visit (pg/ml)</measure>
    <time_frame>up to 21 days</time_frame>
    <description>Detecting the mean amount of the biomarker Survivin in the urine of patients prior to starting study agent, at Day 8 and pre-surgery time (when they have been on study agent between 14-21 days). This is measured by urine analysis at each of the time points to serve as a surrogate tumor marker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survivin in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, Survivin, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EGFR Mutations in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of EGFR mutations in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EGFR in Benign Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, EGFR, in the benign tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ki-67 in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, Ki-67, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated Caspase 3 in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, Activated Caspase 3, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COX2 in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, COX2, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AKT in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, AKT, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pAKT in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, pAKT, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAP Kinase in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, MAP Kinase, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pMAP Kinase in Tumor Tissue</measure>
    <time_frame>up to 21 days on Study Drug</time_frame>
    <description>Detecting the signal of the biomarker, pMAP Kinase, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Recurrent Bladder Cancer</condition>
  <condition>Stage I Bladder Cancer</condition>
  <condition>Stage II Bladder Cancer</condition>
  <condition>Stage III Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (lower dose genistein)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (higher dose genistein)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral genistein as in arm I but at a higher dose. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>genistein</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (lower dose genistein)</arm_group_label>
    <arm_group_label>Arm II (higher dose genistein)</arm_group_label>
    <other_name>CI 75610</other_name>
    <other_name>genisteol</other_name>
    <other_name>genisterin</other_name>
    <other_name>prunetol</other_name>
    <other_name>sophoricol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (lower dose genistein)</arm_group_label>
    <arm_group_label>Arm II (higher dose genistein)</arm_group_label>
    <arm_group_label>Arm III (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm III (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
    <arm_group_label>Arm I (lower dose genistein)</arm_group_label>
    <arm_group_label>Arm II (higher dose genistein)</arm_group_label>
    <arm_group_label>Arm III (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (lower dose genistein)</arm_group_label>
    <arm_group_label>Arm II (higher dose genistein)</arm_group_label>
    <arm_group_label>Arm III (placebo)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants eligible for this study will have been evaluated by diagnostic office
             cystoscopy and found to have a bladder tumor; enrollment (signing of the consent form)
             must be within 60 days of pre-study cystoscopy demonstrating bladder tumor; the
             participant should have no evidence of distant metastasis and the primary tumor may
             represent either an initial diagnosis or recurrent disease of any clinical stage.
             Study participants must also be candidates for either subsequent
             cystoscopy/transurethral resection of bladder tumor (TURBT) or complete or partial
             cystectomy; histologic diagnosis is not required for enrollment; pre-enrollment
             diagnostic cystoscopy must be at least 45 days after treatment of the bladder with
             other agents such as BCG (participants with recurrent disease)

          -  ECOG performance status 0 or 1

          -  Women of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation

          -  Ability to understand and the willingness to sign a written informed consent document

          -  WBC &gt;= 3000/mm^3

          -  Platelets &gt;= 100,000mm^3

          -  Hemoglobin &gt;= 10 g/dL

          -  Bilirubin =&lt; 1.4 mg/dl

          -  AST =&lt; 3x normal

          -  Creatinine =&lt; 2.0mg/dl

          -  Serum calcium =&lt; 10.2 mg/dl,

          -  Amylase =&lt; 3 x normal

          -  Na &gt;= 125 and =&lt; 155 mmol/L

          -  K &gt;= 3.2 and =&lt; 6 mmol/L

          -  Cl &gt;= 85 and =&lt; 114 mmol/L

          -  CO2 &gt;= 11 mEQ/dL

          -  TSH within 1.3 x the upper range of normal and normal T4

          -  Females of child-bearing potential must have a negative pregnancy test; patients who
             have had a bilateral oophorectomy, hysterectomy, are greater than 1 year since their
             last menses, or are greater than 51 years of age are not considered to be of
             child-baring potential

          -  Participants must agree to stop soy supplements before enrolling in the study

          -  Patients must agree to stop taking NSAIDS before enrolling in the study; patients may,
             however, take cardioprotective doses of aspirin equal to or less than 81mg per day

        Exclusion Criteria:

          -  Participant may not have received other treatment for bladder cancer between the
             pre-enrollment cystoscopy and subsequent surgery

          -  Participants may not be receiving any other investigational agents

          -  Participant may not have received prior pelvic irradiation for any reason

          -  Participant may not be receiving concurrent systemic cancer treatment for other
             cancers

          -  Participant may not be taking concurrent soy supplements while on the study medication

          -  Participant may not be taking concurrent NSAIDS (aspirin doses of =&lt; 81 mg acceptable)
             while on the study medication

          -  Participant may not be taking thyroid medications

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to genistein, soy isoflavones or other allergies to soy-based products
             will render a participant ineligible

          -  Uncontrolled concurrent illness will render a participant ineligible including,
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, unregulated cardiac arrhythmia, or psychiatric illness/social situations
             that would limit compliance with study requirements

          -  Women may not be pregnant or lactating; the effects of G-2535 on the developing human
             fetus at the recommended therapeutic dose are unknown; for this reason women of
             childbearing potential and men must agree to use adequate contraception (hormonal or
             barrier method of birth control; abstinence) prior to study entry and for the duration
             of study participation; should a woman become pregnant or suspect she is pregnant
             while participating in this study, she should inform her treating physician
             immediately
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Bailey</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Chemoprevention Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin Chemoprevention Consortium</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706-1969</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <results_first_submitted>December 10, 2015</results_first_submitted>
  <results_first_submitted_qc>February 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 24, 2016</results_first_posted>
  <last_update_submitted>May 23, 2017</last_update_submitted>
  <last_update_submitted_qc>May 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited during a 3 year period by staff at 7 participating institutions (both University hospitals and community clinics).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I (300mg Genistein)</title>
          <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
        </group>
        <group group_id="P2">
          <title>Arm II (600mg Genistein)</title>
          <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
        </group>
        <group group_id="P3">
          <title>Arm III (Placebo)</title>
          <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical Contraindication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliant Participant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (300mg Genistein)</title>
          <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
        </group>
        <group group_id="B2">
          <title>Arm II (600mg Genistein)</title>
          <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
        </group>
        <group group_id="B3">
          <title>Arm III (Placebo)</title>
          <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.60" spread="9.16"/>
                    <measurement group_id="B2" value="68.65" spread="9.16"/>
                    <measurement group_id="B3" value="71.95" spread="12.67"/>
                    <measurement group_id="B4" value="69.73" spread="10.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Epidermal Growth Factor Receptor (EGFR) Phosphorylation in Tumor Tissue, as Measured by Immunohistochemistry After the Completion of Treatment</title>
        <description>Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
        </group_list>
        <measure>
          <title>Epidermal Growth Factor Receptor (EGFR) Phosphorylation in Tumor Tissue, as Measured by Immunohistochemistry After the Completion of Treatment</title>
          <description>Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of pEGFR strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.63"/>
                    <measurement group_id="O2" value="83.33"/>
                    <measurement group_id="O3" value="93.33"/>
                    <measurement group_id="O4" value="67.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.35"/>
                    <measurement group_id="O2" value="16.67"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="18.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.32"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="6.67"/>
                    <measurement group_id="O4" value="13.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>BLCA-4 in Urine by Visit</title>
        <description>Detecting the mean amount of the biomarker BLCA-4 in the urine of patients prior to starting study agent, at Day 8 and pre-surgery time (when they have been on study agent between 14-21 days). This is measured by urine analysis at each of the time points to serve as a surrogate tumor marker.</description>
        <time_frame>up to 21 days</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 17 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>BLCA-4 in Urine by Visit</title>
          <description>Detecting the mean amount of the biomarker BLCA-4 in the urine of patients prior to starting study agent, at Day 8 and pre-surgery time (when they have been on study agent between 14-21 days). This is measured by urine analysis at each of the time points to serve as a surrogate tumor marker.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 17 for this outcome.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.35"/>
                    <measurement group_id="O2" value="0.46" spread="0.24"/>
                    <measurement group_id="O3" value="0.52" spread="0.37"/>
                    <measurement group_id="O4" value="0.55" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.42"/>
                    <measurement group_id="O2" value="0.53" spread="0.20"/>
                    <measurement group_id="O3" value="0.54" spread="0.42"/>
                    <measurement group_id="O4" value="0.50" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.36"/>
                    <measurement group_id="O2" value="0.49" spread="0.34"/>
                    <measurement group_id="O3" value="0.59" spread="0.39"/>
                    <measurement group_id="O4" value="0.44" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survivin in Urine by Visit (pg/ml)</title>
        <description>Detecting the mean amount of the biomarker Survivin in the urine of patients prior to starting study agent, at Day 8 and pre-surgery time (when they have been on study agent between 14-21 days). This is measured by urine analysis at each of the time points to serve as a surrogate tumor marker.</description>
        <time_frame>up to 21 days</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 16 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Survivin in Urine by Visit (pg/ml)</title>
          <description>Detecting the mean amount of the biomarker Survivin in the urine of patients prior to starting study agent, at Day 8 and pre-surgery time (when they have been on study agent between 14-21 days). This is measured by urine analysis at each of the time points to serve as a surrogate tumor marker.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 16 for this outcome.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="141.3"/>
                    <measurement group_id="O2" value="16.0" spread="37.4"/>
                    <measurement group_id="O3" value="71.0" spread="171.7"/>
                    <measurement group_id="O4" value="46.6" spread="108.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="123.8"/>
                    <measurement group_id="O2" value="17.8" spread="32.6"/>
                    <measurement group_id="O3" value="60.3" spread="175.7"/>
                    <measurement group_id="O4" value="23.7" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre-Surgery</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="166.7"/>
                    <measurement group_id="O2" value="28.6" spread="43.3"/>
                    <measurement group_id="O3" value="84.4" spread="237.3"/>
                    <measurement group_id="O4" value="29.5" spread="49.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survivin in Tumor Tissue</title>
        <description>Detecting the signal of the biomarker, Survivin, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Survivin in Tumor Tissue</title>
          <description>Detecting the signal of the biomarker, Survivin, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of Survivin strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.32"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="15.79"/>
                    <measurement group_id="O4" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.51"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="15.79"/>
                    <measurement group_id="O4" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.14"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="26.32"/>
                    <measurement group_id="O4" value="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.03"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="42.11"/>
                    <measurement group_id="O4" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EGFR Mutations in Tumor Tissue</title>
        <description>Detecting the signal of EGFR mutations in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>EGFR Mutations in Tumor Tissue</title>
          <description>Detecting the signal of EGFR mutations in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of EGFR strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.65"/>
                    <measurement group_id="O2" value="46.67"/>
                    <measurement group_id="O3" value="42.11"/>
                    <measurement group_id="O4" value="55.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.22"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="10.53"/>
                    <measurement group_id="O4" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.22"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="21.05"/>
                    <measurement group_id="O4" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.92"/>
                    <measurement group_id="O2" value="46.67"/>
                    <measurement group_id="O3" value="26.32"/>
                    <measurement group_id="O4" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>pEGFR in Benign Tissue</title>
        <description>Detecting the signal of the biomarker, pEGFR, in the benign tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>pEGFR in Benign Tissue</title>
          <description>Detecting the signal of the biomarker, pEGFR, in the benign tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV.</population>
          <units>percentage of pEGFR strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.55"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="7.14"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.27"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="28.57"/>
                    <measurement group_id="O4" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.55"/>
                    <measurement group_id="O2" value="44.44"/>
                    <measurement group_id="O3" value="57.14"/>
                    <measurement group_id="O4" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64"/>
                    <measurement group_id="O2" value="22.22"/>
                    <measurement group_id="O3" value="7.14"/>
                    <measurement group_id="O4" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EGFR in Benign Tissue</title>
        <description>Detecting the signal of the biomarker, EGFR, in the benign tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>EGFR in Benign Tissue</title>
          <description>Detecting the signal of the biomarker, EGFR, in the benign tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV.</population>
          <units>percentage of EGFR strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.91"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="42.86"/>
                    <measurement group_id="O4" value="37.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64"/>
                    <measurement group_id="O2" value="22.22"/>
                    <measurement group_id="O3" value="7.14"/>
                    <measurement group_id="O4" value="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="14.29"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.36"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="35.71"/>
                    <measurement group_id="O4" value="37.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ki-67 in Tumor Tissue</title>
        <description>Detecting the signal of the biomarker, Ki-67, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Ki-67 in Tumor Tissue</title>
          <description>Detecting the signal of the biomarker, Ki-67, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of Ki-67 strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.54"/>
                    <measurement group_id="O2" value="26.67"/>
                    <measurement group_id="O3" value="47.37"/>
                    <measurement group_id="O4" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.92"/>
                    <measurement group_id="O2" value="20.00"/>
                    <measurement group_id="O3" value="15.79"/>
                    <measurement group_id="O4" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.14"/>
                    <measurement group_id="O2" value="46.67"/>
                    <measurement group_id="O3" value="31.58"/>
                    <measurement group_id="O4" value="38.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="5.26"/>
                    <measurement group_id="O4" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activated Caspase 3 in Tumor Tissue</title>
        <description>Detecting the signal of the biomarker, Activated Caspase 3, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>Activated Caspase 3 in Tumor Tissue</title>
          <description>Detecting the signal of the biomarker, Activated Caspase 3, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of Caspase 3 strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.81"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="10.53"/>
                    <measurement group_id="O4" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.03"/>
                    <measurement group_id="O2" value="26.67"/>
                    <measurement group_id="O3" value="26.32"/>
                    <measurement group_id="O4" value="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.46"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="63.16"/>
                    <measurement group_id="O4" value="55.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COX2 in Tumor Tissue</title>
        <description>Detecting the signal of the biomarker, COX2, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>COX2 in Tumor Tissue</title>
          <description>Detecting the signal of the biomarker, COX2, in the tumor tissue after being on study drug for between 14-21 days as a way to measuring the effects G-2535 have on it with regards to proliferation, apoptosis, and other processes relevant to bladder cancer.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of COX2 strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.51"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="15.79"/>
                    <measurement group_id="O4" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.43"/>
                    <measurement group_id="O2" value="26.67"/>
                    <measurement group_id="O3" value="36.84"/>
                    <measurement group_id="O4" value="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.22"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="5.26"/>
                    <measurement group_id="O4" value="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.84"/>
                    <measurement group_id="O2" value="40.00"/>
                    <measurement group_id="O3" value="42.11"/>
                    <measurement group_id="O4" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AKT in Tumor Tissue</title>
        <description>Detecting the signal of the biomarker, AKT, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>AKT in Tumor Tissue</title>
          <description>Detecting the signal of the biomarker, AKT, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of AKT strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.86"/>
                    <measurement group_id="O2" value="60.00"/>
                    <measurement group_id="O3" value="78.95"/>
                    <measurement group_id="O4" value="50.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.81"/>
                    <measurement group_id="O2" value="13.33"/>
                    <measurement group_id="O3" value="5.26"/>
                    <measurement group_id="O4" value="16.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.92"/>
                    <measurement group_id="O2" value="20.00"/>
                    <measurement group_id="O3" value="10.53"/>
                    <measurement group_id="O4" value="27.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="5.26"/>
                    <measurement group_id="O4" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>pAKT in Tumor Tissue</title>
        <description>Detecting the signal of the biomarker, pAKT, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>pAKT in Tumor Tissue</title>
          <description>Detecting the signal of the biomarker, pAKT, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of pAKT strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.24"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="47.37"/>
                    <measurement group_id="O4" value="38.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.11"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="5.26"/>
                    <measurement group_id="O4" value="11.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.95"/>
                    <measurement group_id="O2" value="60.00"/>
                    <measurement group_id="O3" value="47.37"/>
                    <measurement group_id="O4" value="44.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MAP Kinase in Tumor Tissue</title>
        <description>Detecting the signal of the biomarker, MAP Kinase, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>MAP Kinase in Tumor Tissue</title>
          <description>Detecting the signal of the biomarker, MAP Kinase, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of MAP Kinase strength signal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.68"/>
                    <measurement group_id="O2" value="86.67"/>
                    <measurement group_id="O3" value="84.21"/>
                    <measurement group_id="O4" value="66.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.22"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="10.53"/>
                    <measurement group_id="O4" value="22.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70"/>
                    <measurement group_id="O2" value="0.00"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="5.26"/>
                    <measurement group_id="O4" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>pMAP Kinase in Tumor Tissue</title>
        <description>Detecting the signal of the biomarker, pMAP Kinase, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
        <time_frame>up to 21 days on Study Drug</time_frame>
        <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm IV (300mg Genistein + 600mg Genistein)</title>
            <description>This is a combination analysis those on 300mg of genistein and 600mg genistein</description>
          </group>
          <group group_id="O2">
            <title>Arm III (Placebo)</title>
            <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O3">
            <title>Arm I (300mg Genistein)</title>
            <description>Patients receive oral genistein (150mg) twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
          <group group_id="O4">
            <title>Arm II (600mg Genistein)</title>
            <description>Patients receive oral genistein as in arm I but at a higher dose (600mg). One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.</description>
          </group>
        </group_list>
        <measure>
          <title>pMAP Kinase in Tumor Tissue</title>
          <description>Detecting the signal of the biomarker, pMAP Kinase, in the tumor tissue after being on study drug for between 14-21 days.
Strong, Moderate, Weak, and Negative are categorized based on the signal. The measurements display the strength of the signal between the different Arms.</description>
          <population>For this outcome Arm 1 and Arm II were analyzed together which lead to Arm IV. Also for Arm III although 14 participants successfully completed the study for this group they were able to analyzed 15 for this outcome.</population>
          <units>percentage of pMAP Kinase strength signa</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Strong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.65"/>
                    <measurement group_id="O2" value="66.67"/>
                    <measurement group_id="O3" value="36.84"/>
                    <measurement group_id="O4" value="61.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.84"/>
                    <measurement group_id="O2" value="20.00"/>
                    <measurement group_id="O3" value="42.11"/>
                    <measurement group_id="O4" value="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Weak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.51"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="21.05"/>
                    <measurement group_id="O4" value="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00"/>
                    <measurement group_id="O2" value="6.67"/>
                    <measurement group_id="O3" value="0.00"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of randomization until end of study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Lower Dose Genistein)</title>
          <description>Patients receive oral genistein twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
genistein: Given orally
laboratory biomarker analysis: Correlative studies
therapeutic conventional surgery: Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Higher Dose Genistein)</title>
          <description>Patients receive oral genistein as in arm I but at a higher dose. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
genistein: Given orally
laboratory biomarker analysis: Correlative studies
therapeutic conventional surgery: Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
pharmacological study: Correlative studies</description>
        </group>
        <group group_id="E3">
          <title>Arm III (Placebo)</title>
          <description>Patients receive oral placebo twice daily for approximately 14-30 days. One day after completion of genistein or placebo, all patients undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
laboratory biomarker analysis: Correlative studies
placebo: Given orally
therapeutic conventional surgery: Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
pharmacological study: Correlative studies</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular arrhythmia- Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>decreased red blood cells</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>elevated hematocrit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>elevated platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>elevated white blood cells</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>high platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>leukocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>low hematocrit</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Heartburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>pain: Breast</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain: Esophagus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain: Muscle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>lupus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection of brochus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection of upper airway</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection of urinary tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>amylase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Bicarbonate, serum low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated Bilirubin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>decreased bilirubin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>decreased bun</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated bun</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated Chloride</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>High chloride</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypercalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypoatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>lipase</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>low chloride</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>low creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>low protein in blood work</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Low total bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fullness in left jaw area</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>muscle weakness extremity-upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>excess phlegm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itiching</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard H. Bailey, M.D.</name_or_title>
      <organization>University of Wisconsin</organization>
      <phone>608-263-8624</phone>
      <email>hhbailey@wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

